Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02448420
Title	Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer (PATRICIA II)
Acronym	PATRICIA II
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	SOLTI Breast Cancer Research Group
Indications	Her2-receptor positive breast cancer
Therapies	Eribulin + Trastuzumab Fulvestrant + Palbociclib + Trastuzumab Ado-trastuzumab emtansine + Trastuzumab Palbociclib + Tamoxifen + Trastuzumab Anastrozole + Palbociclib + Trastuzumab Capecitabine + Trastuzumab Gemcitabine + Trastuzumab Palbociclib + Trastuzumab Exemestane + Palbociclib + Trastuzumab Trastuzumab + Vinorelbine Letrozole + Palbociclib + Trastuzumab
Age Groups:	adult \| senior
Covered Countries	ESP